MICROBIAL CONTROL AND IDENTIFICATION

STRATEGIES

METHODS

APPLICATIONS

Dona Reber and Mary Griffin
Editors

www.pda.org/bookstore
Microbial Control
and Identification

Strategies
Methods
Applications

Dona Reber and Mary Griffin
Editors

To order this book, please visit: go.pda.org/MCID

PDA
Bethesda, MD, USA

DHI Publishing, LLC
River Grove, IL, USA

www.pda.org/bookstore
10 9 8 7 6 5 4 3 2 1

Copyright © 2018 Dona Reber and Mary Griffin
All rights reserved.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The authors have made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.

PDA®
Connecting People, Science and Regulation®

This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

PDA Global Headquarters
Bethesda Towers, Suite 600
4350 East-West Highway
Bethesda, MD 20814
United States
www.pda.org/bookstore
001-301-986-0293

Davis Healthcare International Publishing, LLC
2636 West Street
River Grove
IL 60171
United States
www.DHIBooks.com

www.pda.org/bookstore
We dedicate this book to Cynthia Sarnoski, Ph.D., our long-time mentor and advisor who offered invaluable encouragement and support throughout the writing and editing of this book.
Contents

5 QUALITY RISK MANAGEMENT IN THE CONTEXT OF VIRAL CONTAMINATION 117
Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
Introduction 117
Use of QRM Tools 124
Initiation of Risk Management Process 146
Risk Assessment 149
Risk Control 153
Result of Risk Management Process 156
Risk Review 161
References 161
About the CAACB 163

6 TRENDING OF MICROBIOLOGICAL ISOLATES IN THE BIOPHARMACEUTICAL ENVIRONMENT 165
Dona Reber
Regulations and Guidelines 166
Uses for EM Trending 168
EM Sample Types of Monitoring Trended 172
Trending Frequency 172
Microbial Identification Strategy 174
Steps in Isolate Trending 176
Conclusion 191
References 191
About the Author 194

7 BURKHOLDERIA CEPACIA COMPLEX: CHARACTERISTICS, PRODUCT RISK, AND TESTING ASSESSMENTS 197
Tim Sandle
Introduction 197
Organism Characteristics 199
Origins in Pharmaceutical and Healthcare 200
Potential Risk to Patients 203
FDA Alert and the Testing Debate 204
Testing Scope 212
SECTION 2 – METHODOLOGIES

8 OVERVIEW OF CONVENTIONAL AND EMERGING MICROBIAL IDENTIFICATION METHODS 231
Frank E. Matos and Jennifer R. Reyes
Introduction 231
Microbial Identification: What Method to Use 232
Isolation of Microorganisms in Pure Culture 234
Methods for Characterization and Preliminary Screening 235
Phenotypic Methods for Microbial Identification 241
Fatty Acid Analysis Using the Midi Sherlock® 246
MALDI-TOF 248
Genotypic Methods for Bacterial Identification 249
Ribotyping 254
Identification of Fungi 258
Molecular Methods for Fungal Identification 265
Use of Contract Laboratories for Microbial Identification 268
Conclusion 269
References 269
About the Authors 273

9 QUALIFICATION AND IMPLEMENTATION OF MALDI-TOF TECHNOLOGY FOR USE IN A QUALITY CONTROL LABORATORY 275
Jennifer R. Reyes, Frank E. Matos and Gary Kruppa
Introduction: Microbial Identification Using MALDI-TOF Mass Spectrometry 276
In-House Evaluation 285
Qualification Activities 287
Improvements 293
Routine Use Activities 295
References 298
About the Authors 301
SECTION 3 – APPLICATIONS

13 DISINFECTANT PERFORMANCE AGAINST FUNGI, VIRUSES AND BACTERIA 381
James Polarine, Jr., David Shields, and Jennifer Loughman
Introduction 381
Disinfectant and Sporicide Activity against Fungal Spores 382
Disinfectant and Sporicide Activity against Viruses 391
Disinfectant and Sporicide Activity against Bacteria 393
Conclusion 400
References 401
About the Authors 403

14 ENVIRONMENTAL ISOLATES IN PHARMACEUTICAL MANUFACTURING 405
Angel L. Salamán-Byron
Introduction 405
Regulatory and Compendia Guidance 406
Evaluation and Selection of EIs 409
Application EIs in Pharmaceutical Test Methods 421
Conclusion 426
References 427
About the Author 438

15 MANAGING STOCK CULTURES 439
Vanessa Vasadi-Figueroa
Introduction 439
Applications and Use 440
Top Six Lineup 441
Culture Libraries 442
Handling 443
Storage Methods 444
Cryopreservation 446
Lyophilization 448
Culture Recovery 449
Market Availabilities 452
Documentation and Inventory Management 454
Conclusion 454
References 455
About the Author 456
Contents

16 COMPETENCY-BASED TRAINING APPROACH FOR MICROBIAL IDENTIFICATIONS 457
Edward S. Balkovic and Gary C. du Moulin
Scope of Microbiology Based Training 461
Expectations for Establishing the Training Program 462
Expectations for Those Participating in the Training Program 466
Training Material Development 469
Training Phase – Process 474
Training Phase – Task Specific Considerations 478
Assessment Phase 484
Summary 486
References 487
About the Authors 491

17 MOLD CONTAMINATION IN THE PHARMACEUTICAL INDUSTRY 493
Brian G. Hubka and Jeanne Moldenhauer
What is Mold? 493
Why do I Care About Mold? 494
Criteria for Mold Growth 499
Mold Detection and Identification 501
Setting Limits for Mold Contamination 509
Mold Remediation Methods 511
Mold Prevention Methods 514
References 517
About the Authors 520

18 KEY FEATURES OF A BIOSAFETY PROGRAM FOR THE BIOPHARMACEUTICAL INDUSTRY 523
Jessica Avizinis
Relevance of Biosafety to Drug Development, Manufacturing and Testing Operations 524
The Importance of Biosafety: Impacts of Exposure 527
Key Features of a Biosafety Program 530
Future Biopharmaceutical Biosafety – Special Challenges 560
Conclusion 561
References 562
About the Author 567

Index 569
Many years have gone by since I first dabbled in microbiology, specifically as it relates to the manufacture of medical products and the impact microbiology has upon the pharmaceutical industry worldwide. I would have greatly appreciated being better versed back in those days with *Strategies, Methods, Applications*, all topics that remain to be within our focus and scientific realm of interest.

The book’s stable of authors are subject matter experts, world renowned and highly respected microbiologists in their respective field of science. That said, you will appreciate reading their depth and breadth of experience regarding current microbiological challenges. For example, Cundell, Moldenhauer, Mateffy and Sandle provide their perspectives on strategies that you will find worthy of your consideration.

The microbiological control and identification as well as microbiological assessment are areas that we all, and quite rightly so, continue to focus our energies and resources. Part and parcel with microbial identification includes trending of the microbial data and corrective measures that may need to be implemented to preclude and/or reduce the presence of microbial and bacterial endotoxin contamination. We all appreciate an inability to escape
from having a scientific discussion without including some form of risk assessment and risk management, which is no less important with regards to viral inactivation. I dare say you will find the chapter worthy of your read.

The rapid microbiological methods (e.g., MicroSEQ®, MALDI-TOF) are more common place in todays’ laboratories and a far cry from someone who used to prepare a sea of the biochemicals, micro-bial test reagents, poured a river of agar plates and yes, indeed I washed my share of test tubes. The chapter includes laboratory equipment qualification considerations that historically may have not been performed by the laboratory staff. The reader will find it rewarding as they come to better understand and better appreciate how the equipment qualification can impact the microbiological results.

There is a subject that has captured much of our time and to a notable extent has stretched precious resources. Jeanne Moldenhauer provides welcomed guidance and perspectives on this subject, Data Integrity, which you will find worthy of consideration to address and implement the necessary measures to preclude the accidental or unintentional deletion or omission of microbiological data.

I continue to assess how well a company understands the microbiological impacts upon the manufacturing processes. Irrespective of whether the commodity is sterile or non-sterile, a comprehensive microbiological assessment is value added to any manufacturing operation. Equally important, which all have heard me say throughout the years, did the comprehensive assessments include a Microbiologist at the discussion table during the evaluation and implementation process. The individual topics within the text are of welcomed value to any organization. That said, when considering the Strategy, Methods and Applications, collectively, I would point out that is not unlike how I might possibly assess a medical products manufacturer.

Thomas J. Arista
June 14, 2018
It has been six years since we edited our initial volume on Microbial Identifications: The Keys to a Successful Program for the PDA and DHI Publishing, LLC. Microbial identification continues to evolve with new technologies and expectations, yet remains so fundamental to microbial control of quality biopharmaceutical products.

We decided it was the perfect time to once again bring together a group of expert microbiologists and biopharmaceutical industry leaders to discuss microbial identifications in a new light, that of how microbial identification knowledge is a cornerstone in the concept of microbial and contamination control programs. The chapters show how microbial control programs for our facilities, equipment and personnel result in a positive impact on our products and ultimately our patients.

Some of these authors were included in our initial volume and we welcome them back for their continued support and excellent and informative chapters: Drs. Anthony M. Cundell, Jeanne Moldenhauer, Martina Kopp and Houman Dehghani. The remaining authors are new for us, but not to our industry by any means – all are
well known for their expertise, and we are very pleased that they have joined us here. Please open the book and you will most likely recognize some of these authors, others are newcomers to writing chapters, and we are delighted they all rose to the challenge.

This book has three sections: Strategies, Methods and Applications. Strategies cover regulations and regulatory expectations as well as strategies for trending, risk assessments, and risk management. Methods include current best practice microorganism identification methods, both conventional and emerging rapid methods for bacteria, viruses, mycoplasma and fungi. Applications include microbiology laboratory training for identifications, use of environmental and control microorganisms, disinfectant effectiveness and best practices, and an up and coming chapter subject, biosafety for laboratories, manufacturing facilities and personnel.

It is recognized that each author has taken time from his or her very busy schedules and free time because of a passion for microbiology and microbial control, and with it the desire to share knowledge with others in our industry. This is very much appreciated by us. We also share this passion and dedication as evidenced by our many years of working and presenting on microbiological issues.

This text will provide valuable information for the new microbiologist as well as a reference for well-seasoned professionals. We sincerely hope you enjoy the book.

Dona Reber and Mary Griffin
June 2018
ABOUT THE EDITORS

Dona Reber has more than 25 years of academic and industrial microbiology experience, including developing and implementing contamination control strategies for aseptic/non aseptic manufacturing, microbiology testing/development, and managing/networking microbiology laboratories. She is Senior Manager of Microbiology and Aseptic Support, Global Quality Operations for Pfizer, responsible for assessing aseptic processing facilities, investigations, troubleshooting, and developing policy documents for microbiology.

Dona holds B.S. and M.S. degrees in related sciences, is (SM) NCRM certified, has been a PDA member for 20+ years, and a longtime chair of the Pharmaceutical Micro Expert Discussion Group. She has numerous publications on microbial identifications systems, environmental monitoring and microbiology risk assessments. She has co-authored three PDA Technical Reports: TR#13, Fundamentals of an Environmental Monitoring Program; TR#67, Exclusion of Objectionable Microorganisms from Non Sterile Pharmaceutical, Medical Devices and Cosmetics; and TR#70,
Fundamentals of Cleaning and Disinfection. She is on a PDA Task Force for Low Bioburden Environmental Monitoring. She has participated in instructing new FDA inspectors, and is an instructor for the PDA on TR#13, Fundamentals of an EM Program. She presented at the most recent PDA Micro Conference on environmental monitoring for low bioburden processes.

Mary Griffin, Principal, MG Quality Microbiology Consulting, LLC, is a subject matter expert in microbiology with more than 35 years of academic (University of Michigan; University of Massachusetts) and global biopharmaceutical experience.

She initiated and directed the Quality Control Microbial Science and Technology department at Pfizer (previously Wyeth, Andover, MA) during a period of significant growth. She adapted her extensive knowledge of microorganisms and classical identification techniques to successfully implement both identification and rapid automated detection systems to keep the facility on the cutting edge of novel technologies.

She continues to support the industry as a consultant through the application of her microbiological identification and rapid technologies expertise for microbial control. She holds a M.S. degree in Microbiology and is certified as a Specialist Microbiologist SM (NRCM). She is an active member of the Parenteral Drug Association (New England Chapter) and is published in the pharmaceutical industry.